Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT01836133
What this trial is testing

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 70
Large-scale testing (Phase 3)Ended earlyNCT02186301
What this trial is testing

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Clovis Oncology, Inc. 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07463677
What this trial is testing

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)
Sun Yat-sen University 55
Testing effectiveness (Phase 2)Ended earlyNCT04044170
What this trial is testing

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Hanmi Pharmaceutical Company Limited 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339839
What this trial is testing

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Who this might be right for
NSCLC Stage IVKRAS G12C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 42
Testing effectiveness (Phase 2)UnknownNCT00082472
What this trial is testing

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

Who this might be right for
NSCLC
Zivena 30
Testing effectiveness (Phase 2)Looking for participantsNCT07287995
What this trial is testing

ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 428
Testing effectiveness (Phase 2)Study completedNCT00113516
What this trial is testing

SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 84
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Testing effectiveness (Phase 2)Ended earlyNCT04069936
What this trial is testing

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung CancerLung CancerLung Cancer Metastatic+5 more
WindMIL Therapeutics 19
Testing effectiveness (Phase 2)UnknownNCT05132777
What this trial is testing

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc. 155
Testing effectiveness (Phase 2)Looking for participantsNCT06929936
What this trial is testing

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung CancerMyelosuppression
The First Affiliated Hospital of Xiamen University 33
Large-scale testing (Phase 3)Active Not RecruitingNCT05261399
What this trial is testing

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Who this might be right for
CarcinomaNon-Small-Cell Lung
AstraZeneca 341
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07630077
What this trial is testing

Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 30
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Early research (Phase 1)Study completedNCT03071757
What this trial is testing

The Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 139
Early research (Phase 1)Study completedNCT05631678
What this trial is testing

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 48
Not applicableApproved For MarketingNCT01931306
What this trial is testing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Early research (Phase 1)Ended earlyNCT02122146
What this trial is testing

PF-06664178 In Patients With Advanced Solid Tumors

Who this might be right for
Neoplasms
Pfizer 31
Next Page